Atrium Therapeutics, Inc. RNA
- Market cap
- $140.1M
- P/E
- 0.0×
Follow RNA
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 0 | 2 | 7 | 9 | 9 | 10 | 11 | 19 |
Revenue
|
|||
| — | — | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| — | — | (11) | (25) | (44) | (118) | (174) | (212) | (322) | (685) |
EBT
|
|||
| — | — | (2,959.37%) | (1,066.58%) | (653.53%) | (1,265.38%) | (1,886.33%) | (2,219.87%) | (2,957.71%) | (3,650.39%) |
EBT Margin
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PS Ratio
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/FCF
|
|||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | 85 | 317 | 381 | 571 | 531 | 1,444 | 1,603 |
Working Cap'
|
|||
| — | — | — | 2 | — | — | — | — | — | — |
Total Debt
|
|||
| — | — | — | (93) | (328) | (406) | (611) | (595) | (1,501) | (1,697) |
Net Debt
|
|||
| — | — | — | 69 | 306 | 381 | 578 | 501 | 1,425 | 1,689 |
Sh' Equity
|
|||
| — | — | 0.00% | (51.05%) | (20.59%) | (30.99%) | (32.63%) | (33.49%) | (29.40%) | (38.88%) |
ROA
|
|||
| — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | 0.00% | 0.00% | 99.98% | 94.00% | 64.08% | 45.67% | 44.04% | 55.42% |
ROE
|
|||
Atrium Therapeutics, Inc. (RNA) key facts
- Atrium Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 72.1% from fiscal 2024.
- As of September 25, 2026, RNA traded at $8.29, a market capitalization of $140.1 million.
- Return on equity was 55.4% and debt-to-equity 0.00.
Atrium Therapeutics, Inc. (RNA) Latest News
21 Sep
Atrium Therapeutics announced inducement grants under Nasdaq Rule 5635(c)(4) to one new hire, consisting of non-qualified stock options to buy 13,500 shares at $8.95 and RSUs for 6,750 shares; 25% of options and 25% of RSUs vest after one year, with the remainder vesting over three years or in annual installments, approved by the independent Human Capital Management Committee under the 2026 Inducement Plan. The company highlights its RNA-delivery platform targeting the heart, cites FDA IND clearance for ATR 1072 for PRKAG2 syndrome, and advances the Corventis Phase 1/2 trial; the pipeline also includes ATR 1086 for PLN cardiomyopathy and two undisclosed targets. IND clearance for ATR 1072 and pipeline progress provide meaningful clinical momentum, while the one-new-hire inducement grant is a minor, routine item.
6 Sep
Wall Street investors are withdrawing funds from Atrium Therapeutics (RNA) even as its drug pipeline advances toward commercialization. Investor outflows amid pipeline progress point to major near-term pressure on RNA valuation and trajectory.
28 Aug
Atrium Therapeutics (RNA) receives $15 million milestone payment from Bristol-Myers Squibb (BMY) validating its RNA platform. $15 million milestone from Bristol-Myers Squibb affirms RNA platform viability and strengthens long-term prospects.
13 Aug
Atrium Therapeutics, Inc. (RNA) reported financial results for the second quarter of 2026. Quarterly earnings releases deliver performance data that can shift near-term stock valuation and sentiment.
Atrium Therapeutics earns a $15 million milestone payment from Bristol Myers Squibb under their global cardiovascular collaboration. Milestone payment strengthens near-term cash position under existing partnership without major trajectory shifts.
14 Jul
Atrium Therapeutics receives FDA clearance for its Investigational New Drug Application for ATR 1072 to treat PRKAG2 Syndrome. FDA clearance of IND for ATR 1072 advances clinical development and positions company for potential pipeline progress in rare disease treatment.
28 May
Atrium Therapeutics' cash burn situation does not raise major concerns, with analysis pointing to sufficient resources and stable financial positioning for ongoing operations. Reassurance on cash burn supports improved investor sentiment around financial stability without altering core operations.
23 Apr
Atrium Therapeutics earns a $15 million milestone payment from Bristol Myers Squibb under their global cardiovascular collaboration. Milestone payment confirms progress in cardiovascular collaboration with major partner but delivers limited immediate financial impact.
19 Mar
Atrium Therapeutics, Inc. (RNA) emerges as Novartis acquisition spin-off to pioneer RNA therapeutics targeting heart disease. Spin-off launches Atrium as dedicated RNA platform for cardiovascular disease with transformative commercial potential.
17 Mar
Novartis raises $11 billion bond to fund $12 billion deal with Avidity Biosciences (RNA). The $12 billion Novartis deal represents a transformative acquisition or strategic shift that redefines RNA's competitive position and long-term outlook.
27 Feb
Atrium Therapeutics launches with approximately $270 million to advance novel RNA medicines for rare genetic cardiomyopathies. Launch with $270 million positions the company to develop groundbreaking RNA therapies for genetic heart diseases.
Novartis completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy. Acquisition by Novartis transforms Avidity Biosciences from independent entity to subsidiary with redefined competitive position and long-term prospects.
Avidity (RNA) has moved the date for the shareholder vote on its merger with Novartis. The Novartis merger vote date shift signals a major strategic development with strong potential to alter RNA's trajectory and investor sentiment.
Atrium Therapeutics spins out of Avidity to develop RNA therapies for rare heart diseases. Spin-out creates independent company dedicated to RNA therapies for rare cardiac diseases, enabling major strategic focus and trajectory shift.
18 Feb
Atrium Therapeutics published Phase 1/2 MARINA trial results for del-desiran in myotonic dystrophy type 1 treatment in The New England Journal of Medicine. Positive Phase 1/2 trial data in NEJM strengthens del-desiran development path and company valuation.
2 Feb
Avidity Biosciences announces expected record date for spin-off involving Atrium Therapeutics, Inc. (RNA). Spin-off record date announcement signals major corporate restructuring directly affecting Atrium Therapeutics (RNA) trajectory.